Overview

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline